With its professional R&D system, KPC has always maintained close links with government institutions, medical experts and academic organizations both at home and abroad. With a pioneering attitude and a broad view of the future, it continues to provide the most advanced medicine for people worldwide.
From 2005 to 2014, KPC has conducted clinical trials on new antimalarials and medicines to treat cardio-cerebrovascular diseases in multiple countries (including Nigeria, Sudan, Cote d'Ivoire, Uganda, Benin, Congo-Kinshasa, Tanzania, Papua New Guinea, Indonesia, Myanmar, Cameroon and Vietnam). After seven years of international multi-center clinical research, compound naphthoquine phosphate tablets have now been demonstrated to be capable of curing drug-resistant non-complex malaria with administration of a single dose, which built a milestone in the history of the fight against malaria.
